

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
11 August 2005 (11.08.2005)

PCT

(10) International Publication Number  
**WO 2005/073731 A2**

- (51) International Patent Classification<sup>7</sup>: **G01N 33/68**
- (21) International Application Number:  
PCT/GB2005/000328
- (22) International Filing Date: 27 January 2005 (27.01.2005)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
0402123.4 30 January 2004 (30.01.2004) GB
- (71) Applicant (for all designated States except US):  
**PROTHERICS MOLECULAR DESIGN LIMITED**  
[GB/GB]; The Health Business and Technical Park, Runcorn, Cheshire WA7 4QF (GB).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **DOWNHAM, Matthew, Richard** [GB/GB]; The Health Business and Technical Park, Runcorn, Cheshire WA7 4QF (GB). **GLOVER, James, Francis** [GB/GB]; The Health Business and Technical Park, Runcorn, Cheshire WA7 4QF (GB). **HANILY, Rachel, Emma** [GB/GB]; The Health Business and Technical Park, Runcorn, Cheshire WA7 4QF (GB).
- (74) Agent: **COCKBAIN, Julian**; Frank B. Dehn & Co., 179 Queen Victoria Street, London EC4V 4EL (GB).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**  
— without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: CJD PRION TESTING

(57) **Abstract:** The present invention provides an assay method for detecting infectious prion protein in a sample from a mammalian subject, said method comprising: obtaining a prion protein containing sample from said subject; contacting said sample with an agent which serves to digest non-infectious prion protein and to partially digest infected prion protein to yield a prion protein polypeptide residue; contacting the digested sample with an antibody capable of binding to a polypeptide having the amino acid sequence Vc (Gly-Gly-Gly-Trp)-Gly-Gln-Gly-Gly-R<sub>1</sub>-R<sub>2</sub>-His -R<sub>3</sub>-Gln-Trp-Asn-Lys-Pro-R<sub>4</sub>-Lys-Pro-Lys-Thr-R<sub>5</sub>-R<sub>6</sub>-Lys (-His-R<sub>7</sub>-Ala-Gly) (Vc) and detecting conjugates of said antibody and said prion protein polypeptide residue; characterized in that the detection of said conjugates comprises chemical, biological or biochemical amplification of a detectable species and detection of the amplified species.



WO 2005/073731 A2

### CJD Prion Testing

5           This invention relates to improvements in and relating to assay methods for testing for transmissible spongiform encephalopathy (TSE) in mammalian subjects.

          Spongiform encephalopathies are a group of degenerative neurological diseases. Examples have been  
10       found in a number of mammalian species including sheep (where it is known as scrapie), cows (BSE) and humans (Creutzfeldt-Jakob disease (CJD), new variant CJD (nv CJD) and kuru). It has been reported that TSE from one species can be transmitted under laboratory conditions  
15       to mammals of another species. This crossing of species barriers by the infective agent has led to widespread concern that transfer to humans can occur as a result of ingestion of material from an infected food animal, in particular materials of bovine origin.

20           TSEs are characterised by a slow incubation time after which the clinical symptoms of progressive degeneration of mental state, including aggressiveness and lack of coordination, appear. Post mortems reveal a characteristic pattern of vacuolation in brain tissue  
25       due to the destruction of neural cells, and the deposition of unusual protein fibres.

          Although the form of the disease found in sheep has been known for many years, spongiform encephalopathies have come to greater prominence following the appearance  
30       of BSE in cattle and of nvCJD in humans.

          It is believed that the causative agent of TSE is a so-called "prion", that is an infective agent comprising protein only and no nucleic acid. In TSE, one particular protein (termed prion protein, PrP) has been  
35       identified as the infective agent. PrP is a naturally occurring cellular protein that exists in two isoforms which differ in their tertiary structure and as a result

- 2 -

may be distinguished by their response to enzymatic degradation, e.g. by proteinase K. Thus the non-infectious isoform niPrP is wholly digested by proteinase K while the infectious isoform iPrP is degraded to leave a detectable polypeptide residue PrP27-30.

The amino acid sequences for many mammalian PrP are known and accessible, for example on SwissProt. The amino acid sequences for the residue PrP27-30 are likewise known. There is a high degree of homology between the different mammalian PrP sequences.

Several companies have developed post mortem diagnostic tests for TSE, generally based on the use of antibodies which bind to PrP27-30 deriving from a proteolytically digested brain tissue sample.

One such assay available from Enfer, Dublin, Ireland, uses the technology described in EP-B-616613. More particularly the Enfer assay uses two polyclonal antibodies raised against immunogenic conjugates of polypeptide sequences corresponding (i) to a section of PrP27-30 and (ii) to a section of PrP outside the PrP27-30 section. These sections are referred to in EP-B-616613 as Vc and Va respectively.

While the commercial assays have met with some success there is a continuing need for improved TSE assays and in particular for assays that may be performed ante-mortem or which do not require brain tissue samples.

The present invention provides just such an improved assay.

Thus viewed from one aspect the invention provides an assay method for detecting infectious prion protein in a sample from a mammalian subject, said method comprising: obtaining a prion protein containing sample from said subject; contacting said sample with an agent which serves to digest non-infectious prion protein and to partially digest infected prion protein to yield a

- 3 -

prion protein polypeptide residue; contacting the digested sample with an antibody capable of binding to a polypeptide having the amino acid sequence Vc

5 (Gly-Gly-Gly-Trp)-Gly-Gln-Gly-Gly-R<sub>1</sub>-R<sub>2</sub>-His-R<sub>3</sub>-Gln-Trp-Asn-Lys-Pro-R<sub>4</sub>-Lys-Pro-Lys-Thr-R<sub>5</sub>-R<sub>6</sub>-Lys(-His-R<sub>7</sub>-Ala-Gly)  
(Vc)

(wherein R<sub>1</sub> is either Gly or absent;  
10 R<sub>2</sub> is either Thr or Ser;  
R<sub>3</sub> is an amino acid residue selected from Gly, Ser and Asn;  
R<sub>4</sub> and R<sub>5</sub> are each independently either Asn or Ser;  
R<sub>6</sub> is an amino acid residue selected from Met, Leu and  
15 Phe;  
R<sub>7</sub> is either Val or Met; and wherein one or more residues within brackets may be present or absent with the proviso that if they are present they are attached to the rest of the peptide in sequence); and detecting  
20 conjugates of said antibody and said prion protein polypeptide residue; characterized in that the detection of said conjugates comprises chemical, biological or biochemical amplification, especially preferably biochemical or biological amplification, of a detectable  
25 species and detection of the amplified species.

The antibody capable of binding to Vc is preferably an antibody raised against an immunogenic conjugate of a synthetic polypeptide of amino acid sequence Vc (or more preferably Vc' as described below), e.g. by vaccination  
30 of a mammal therewith and collection of sera or Vc-binding IgG.

The prion protein containing sample used in the method of the invention may be a sample of any body tissue, fluid or material which contains prion proteins,  
35 e.g. muscle, tonsil, brain, blood, urine, faeces, etc. The sample may also be blood, serum or plasma from blood banks, blood products (e.g. coagulation factors), tissue

- 4 -

products, culture media containing mammalian products (e.g. BSA), pharmaceutical components derived from mammalian species (e.g. heparin), etc. For post-mortem testing, brain tissue will desirably be used due to its high prion content. For ante-mortem testing the sample is preferably a biopsy tissue sample, blood, urine or faeces. The sample is preferably pretreated to lyse any cells therein, e.g. by homogenization or other tissue disruptive methods.

10       The sample is then contacted with the prion protein digesting agent, e.g. proteinase K, under conditions and for a period sufficient for digestion of the non-infectious prion protein. Such treatments and treatment conditions and durations are well known in the art.

15       If desired the sample may be treated before and/or after digestion to separate out sample components and/or digestion products other than undigested or partially digested prion protein, e.g. by centrifugation, chromatography, etc.

20       Following digestion, the sample is contacted with the Vc-binding antibody. This may be prepared as described in EP-B-616613. Particularly preferably the antibody is prepared using a conjugate of a polypeptide of sequence

25       GQGGSHSQWNKPSKPKTNMKHVG C (Vc')

with an immunogenic carrier, e.g. tetanus toxoid, ovalbumin, etc. Conjugation may be effected using a standard linking agent, e.g. m-maleimido-benzoyl-N-hydroxy sulphosuccinimide ester (SMBS), etc. The antibody is preferably polyclonal. Standard antibody production techniques may be used.

30       The Vc-binding antibody may be immobilized on a substrate (e.g. a flat surface, optionally superparamagnetic beads, rods, meshes, tubes, etc) using conventional protein immobilization techniques.

- 5 -

Alternatively, a non-immobilized Vc-binding antibody may be used.

The precise series of steps in the detection stage of the assay method will depend on whether an  
5 immobilized or non-immobilized Vc-binding antibody is used and on the technique selected for chemical, biological or biochemical amplification.

By chemical amplification it is meant that a non-biochemical chemical reaction (e.g. a reaction catalysed  
10 by a chemical substance not normally found in a biological environment) is used to generate a detectable species, the presence or absence of which is indicative of the presence of antibody:prion protein polypeptide residue conjugates.

By biological amplification it is meant that a  
15 microorganism is used to generate a detectable species (e.g. chemical substance, microorganisms, etc), the presence or absence of which is indicative of the presence of antibody:prion protein polypeptide residue  
20 conjugates.

By biochemical amplification it is meant that a biochemical reaction (e.g. an enzymatic reaction or a nucleic acid amplification such as PCR) is used to  
25 generate the detectable species (e.g. chemical substance), the presence or absence of which is indicative of the presence of antibody:prion protein polypeptide residue conjugates.

The material which is amplified or which causes the amplification to occur may be conjugated to the Vc-  
30 binding antibody or to a further agent capable of binding to the antibody:residue conjugates, e.g. a second antibody. Where it is conjugated to the Vc-binding antibody, its ability to function may be unaffected by conjugation to the PrP27-30 or it may be  
35 activated or deactivated by such conjugation. As a result, unreacted antibody may or may not have to be separated from antibody:residue conjugates. This is

- 6 -

conventional in immunoassay procedures and the person of ordinary skill will readily appreciate the steps that should be taken. Where the material which is to be amplified or which causes amplification is separate from the Vc-binding antibody, it will generally be necessary to separate unconjugated antibody from the antibody:residue conjugates. Again this is conventional in immunoassay procedures and the person of ordinary skill will readily appreciate the steps that should be taken.

The material which is amplified or which causes amplification may comprise more than one component. In this case, one of the components may be conjugated to the Vc-binding antibody and the other to a separate agent capable of binding to the antibody:residue conjugate. Once again it will be clear to the person of ordinary skill whether separation of unconjugated Vc-binding antibody from antibody:residue conjugates is required. Where such a two or more component system is used, it is preferably the case that the different components together create a different amplification effect from that achievable with the single components on their own, e.g. they may be catalysts (e.g. enzymes) that catalyse different stages of a multistage reaction or they may be viral agents having different effects on the same or different target microorganisms.

Where a second binding agent is used in the assay method of the invention this is preferably also an antibody. However other binding agents may be used if desired.

The term antibody as used herein, unless the content dictates otherwise, may be an antibody as such or a functional fragment (e.g. a Fab fragment) thereof, a single chain antibody or an oligomeric antibody construct. Such materials may be produced in conventional fashion.

To avoid unnecessary false negatives, the assay

- 7 -

method of the invention also preferably involves testing a portion of the original sample for PrP content. This may be done conventionally, e.g. using PrP binding antibodies as for example in the commercial BSE tests.

5 In this case, the PrP binding antibody should be capable of binding to iPrP and/or niPrP or fragments thereof exposed by denaturation or partial digestion. Such antibodies are described in the literature.

10 However in a preferred embodiment, a Va-binding antibody is used on non-PK-digested samples, i.e. analogously to the Vc-binding antibodies with the omission of the niPrP digestion step. Particularly preferably the antibody used is a Va-binding antibody as defined below. Especially preferably such an antibody  
15 is one raised against an immunogenic conjugate of a synthetic polypeptide of amino acid sequence Va (or more preferably Va' as described below), e.g. by vaccination of a mammal therewith and collection of sera or Va-binding IgG.

20 By a Va-binding antibody is meant one capable of binding to a polypeptide of sequence

(Pro-Gly-Gly-R<sub>8</sub>)-Trp-Asn-Thr-Gly-Gly-Ser-Arg-Tyr-Pro-Gly-  
Gln-Gly-Ser-Pro-Gly-Gly-Asn-Arg-Tyr-Pro-Pro-Gln-Gly-  
25 (Gly-R<sub>9</sub>-R<sub>10</sub>-Trp) (Va)

wherein R<sub>8</sub> and R<sub>9</sub> are each independently either Gly or absent;

R<sub>10</sub> is either Gly or Thr; and wherein one or more  
30 residues within brackets may be present or absent with the proviso that if they are present they are attached to the rest of the peptide in sequence.

This may be prepared as described in EP-B-616613. Particularly preferably the antibody is prepared using a  
35 conjugate of a polypeptide of sequence This may be prepared as described in EP-B-616613. Particularly preferably the antibody is prepared using a conjugate of

- 8 -

a polypeptide of sequence

GGWNTGGSRYPGQGSPGGNRYPPQGGGC (Va')

5 with an immunogenic carrier, e.g. tetanus toxoid, ovalbumin, etc. Conjugation may be effected using a standard linking agent, e.g. SMBS. The antibody is preferably polyclonal. Standard antibody production techniques may be used.

10 Where an ante-mortem TSE assay result is positive, it is preferable to treat the subject with a therapeutic agent comprising a Vc-binding antibody. This may be the antibody alone or may be a conjugate of the antibody with an agent which serves to hinder the transformation  
15 of niPrP to iPrP or to degrade the iPrP. In the case of human TSE, the therapeutic antibody is preferably a selected antibody (i.e. an anti-Vc or anti-Va antibody as defined above). Administration is preferably by injection or infusion, e.g. into the CSF. Dosages may  
20 be determined conventionally using TSE infected animal models. Such therapeutic use forms a further aspect of the present invention.

Viewed from a further aspect the invention provides a kit for use in the assay method of the invention, said  
25 kit comprising:

- (i) a Vc-binding antibody;
- (ii) optionally and preferably a Va-binding antibody;
- (iii) optionally and preferably proteinase K;
- 30 (iv) a material capable of chemical, biological or biochemical amplification, preferably biological or biochemical amplification, and detection or of causing chemical, biological or biochemical amplification, preferably  
35 biological or biochemical amplification, of a detectable species, said material optionally being conjugated to antibody (i); and

- 9 -

(v) optionally and preferably instructions for the performance of said assay method

While the material (iv) may be an enzyme or other catalyst it is preferably a substance which is itself replicated in the amplification procedure.

The invention will now be described further with reference to the following non-binding Examples:

#### 10 Example 1

##### Sample Preparation

Initial tissue disruption using appropriate methods such as homogenisation in a detergent buffer using pestle and centrifuge tube to produce a crude homogenate which may be clarified by centrifugation. The tissue homogenate sample is diluted to a working concentration in a suitable buffer in readiness for Proteinase K digestion.

#### 20 Example 2

##### Prion Protein Digestion

To distinguish iPrP from niPrP the detection systems rely on the relative resistance of iPrP to digestion by the enzyme proteinase K (PK) (see Kretzschmar, *Clin Lab Med.* P109-128 (2003)). Typical conditions of PK treatment would be, diluted homogenate sample split into two equal portions and PK added to one portion and incubated accordingly (e.g. for 30 mins at 37°C).

30

#### Example 3

##### Vc-Binding Antibody Addition

Serum or purified IgG are prepared from the blood of animals immunised with Vc peptide conjugate vaccine. These sera would then be diluted to a working concentration, contacted with the PK digested

- 10 -

homogenised sample and incubated accordingly (e.g. for 1 hour at 20-25°C).

#### Example 4

##### 5 Signal Amplification and Detection

Signal amplification would typically require applying biochemical techniques, molecular or conjugated secondary antibody techniques. One example would be the  
10 incubation of an antibody conjugated with biotin molecules (e.g. for 1 hour at 20-25°C) amplified by the addition of Avidin (biotin binding agent) conjugated to horse radish peroxidase (e.g. for 1 hour at 20-25°C) and  
15 detection using a chromogenic substrate, read at a specific absorbance on a spectrophotometer.

#### Example 5

##### Antibody Efficacy

20 Vc-binding and Va-binding polyclonal antibodies prepared by animal immunization with antigenic conjugates of Vc' and Va' respectively were contacted with brain homogenate prepared as described above from CJD infected and non-infected human brain with and without proteinase  
25 K digestion. The samples were then subjected to Western blot analysis and the results are shown in accompanying Figures 1 and 2. Figures 1 and 2 are for Va-binding and Vc-binding antibodies respectively. In each Figure, lane 1 is uninfected homogenate, lane 2 is PK treated  
30 uninfected homogenate, lane 3 is infected homogenate, and lane 4 is PK-treated infected homogenate.

- 11 -

Claims:

1. An assay method for detecting infectious prion protein in a sample from a mammalian subject, said  
5 method comprising: obtaining a prion protein containing sample from said subject; contacting said sample with an agent which serves to digest non-infectious prion protein and to partially digest infected prion protein to yield a prion protein polypeptide residue; contacting  
10 the digested sample with an antibody capable of binding to a polypeptide having the amino acid sequence Vc

(Gly-Gly-Gly-Trp)-Gly-Gln-Gly-Gly-R<sub>1</sub>-R<sub>2</sub>-His-R<sub>3</sub>-Gln-Trp-  
Asn-Lys-Pro-R<sub>4</sub>-Lys-Pro-Lys-Thr-R<sub>5</sub>-R<sub>6</sub>-Lys(-His-R<sub>7</sub>-Ala-Gly)  
15 (Vc)

(wherein R<sub>1</sub> is either Gly or absent;  
R<sub>2</sub> is either Thr or Ser;  
R<sub>3</sub> is an amino acid residue selected from Gly, Ser and  
20 Asn;  
R<sub>4</sub> and R<sub>5</sub> are each independently either Asn or Ser;  
R<sub>6</sub> is an amino acid residue selected from Met, Leu and Phe;  
R<sub>7</sub> is either Val or Met; and wherein one or more residues  
25 within brackets may be present or absent with the proviso that if they are present they are attached to the rest of the peptide in sequence); and detecting conjugates of said antibody and said prion protein polypeptide residue; characterized in that the detection  
30 of said conjugates comprises chemical, biological or biochemical amplification of a detectable species and detection of the amplified species.

2. A method as claimed in claim 1 wherein said subject  
35 is human, preferably animate.

3. A method as claimed in either of claims 1 and 2 for

- 12 -

detecting infectious prion protein associated with CJD, nvCJD or kuru.

4. A kit for use in the assay method of any one of  
5 claims 1 to 3, said kit comprising:
- (i) a Vc-binding antibody;
  - (ii) optionally a Va-binding antibody;
  - (iii) optionally proteinase K;
  - 10 (iv) a material capable of chemical, biological or biochemical amplification and detection or of causing chemical, biological or biochemical amplification of a detectable species, said material optionally being conjugated to antibody (i); and
  - 15 (v) optionally instructions for the performance of said assay method.

5. The use of a iPrP binding antibody in the  
manufacture of a medicament for use in the treatment of  
20 human TSE.




FIG. 1




FIG. 2